nuovi markers bio-molecolari nelle sindromi ... · nuovi markers bio-molecolari nelle sindromi...

93
Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni molecolari in onco-ematologia: dalla diagnosi allo studio della Malattia Residua Minima (MRD)

Upload: others

Post on 02-Sep-2019

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative

La Leucemia Acuta Linfoblastica

Genova, 11 Novembre 2014 Alterazioni molecolari in onco-ematologia:

dalla diagnosi allo studio della Malattia Residua Minima (MRD)

Page 2: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Estimated frequency of specific genotypes in childhood ALL

Hyperdiploid >50, 25,0%

TEL-AML1, 20,0%

E2A-PBX1, 4,0% MLL-AF4, 2,0%

BCR-ABL1, 2,0% BCR-ABL1-like; 9.0% CRLF2, 4,0%

IKZF1, 12,0%

ERG, 3,0%

dic(9;20), 2,0% iAMP21, 2,0%

E2A-HLF, 0,5% Hypodiploid; 0.5% Other MLL-R, 4,0%

Other BCP-ALL, 4,5%

TAL1, 7,0%

TLX3, 2,3% LYL1, 1,4%

TLX1, 3,0% MLL-ENL, 3,0%

ETP; 2.0% Others T-ALL; 1.7%

Modified from Pui et al, Blood. 2012;120:1165

T-ALL

BCP-ALL

Page 3: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Molecular genetic subsets of ALL are age-dependent

<1 1 2 3 4 5 6 7 8 9 10 11 12 13 14

years

Annual incidence rate of childhood ALL

per 106 population

Page 4: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

t(9;22) or BCR/ABL: 33% (SE 9%), N= 27 t(4;11) or MLL/AF4: 30% (SE 10%), N= 23

t(1;19) or E2A/PBX1: 5-J.-EFS 93% (SE 6%), N= 15 t(12;21) orTEL/AML1: 95% (SE 3%), N= 44 >50 chromosomes (hyperdipl.): 86% (SE 3%), N=198 normal karyotype: 78% (SE 3%), N=244

years 0 1 2 3 4 5 6 7 8 9 10 11 12

0

20

40

60

80

100

pEFS

(%)

Prognosis of ALL according to genetics ALL-BFM 90

Page 5: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

ALL Study (year) 70 76 79 81 83 86 90 95 2000 2009

WBC x x x

Total leukemic cell mass (RF) x x x x

Age x x x Sex x CNS x x x x Thymic tumor x x x

Immunophenotype (T vs non-T) sP sP x x x x

No CR to phase Ia x x x x x x x

Prednisone response day 8 x x x x x

MRD x x

t(9;22) BCR-ABL x x x EsPhALL

t(4;11) MLL-AF4 x x x t(12;21) ETV6-RUNX1 x Ploidy x

Childhood ALL trials: criteria for risk group stratification

Page 6: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

p-Su

rviv

al (%

)

0

20

40

60

80

100

Childhood ALL: The Treatment Dilemma

Treatment intensity (number of drugs combined, dose intensity)

0

10

20

30

40

50

p-M

orbi

dity

(sev

ere)

(%)

p-M

orta

lity

(trea

tmen

t rel

taed

) (%

)

0 10

Status at the end of the 1990's

Page 7: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

The questions:

•  How to identify those children (20-25%) who ultimately relapse with disease that is highly refractory to current therapy.

•  How to identify those children (25%, or more?) who are likely „over-treated“ and may well be cured using less intensive regimens resulting in fewer toxicities and long term side effects.

Page 8: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Improved overall survival in childhood acute lymphoblastic leukemia

Hunger SP, Pediatr Blood Cancer 2005;45(7):876–80

Page 9: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

MRD as “surrogate” marker to assess heterogeneity in response to treatment

Page 10: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

MRD detection in Acute Lymphoblastic Leukemia:

Fusion transcripts resulting from chromosomal translocations Immunoglobulin (IG) and T cell Receptor (TR) gene rearrangements Multiparametric Flow cytometry

Page 11: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Variability of the V(D)J region of IG/TR gene rearrangements as patient and clone-specific target for MRD detection

VH 5 ' 3 ' JH

VH primer ASO primer/probe

Junctional (“N”) regions

JH primer

Ig H

DH

Patient Marker Junction Junctional sequence Sensitivity

AC15 Vd2-Dd3 -20 / 9 /-13 TGAAGGGTCTT TCGGGCCCC CACAGTGCTAC 4AN40 Vd2-Dd3 -5 /14 / 0 TGAAGGGTCTTACTACTGTGCCTGTG CACCTGACGTACTT ACTGGGGGATACGCACAGTGCTAC 4AX21 Vd2-Dd3 -1 / 2 / 0 TGAAGGGTCTTACTACTGTGCCTGTGACAC GA ACTGGGGGATACGCACAGTGCTAC 4AA34 Vd2-Dd3 -3 /14 / 0 TGAAGGGTCTTACTACTGTGCCTGTGAC CTTTCACCCTTTTT ACTGGGGGATACGCACAGTGCTAC 5

Initial semi-quantitative ‘dot blot’ analysis by 32P-labelled ASO probes

Page 12: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Germline fluorescent probe

Forward junctional primer

Reverse primer

R Q V N J

MRD detection by monitoring Ig/TcR rerrangements

10-1 10-2 10-3 10-4 PB undil

Page 13: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Advanced RQ-PCR MRD detection in childhood ALL in the AIEOP-BFM 2000 study

•  Germline TaqMan probes;

•  Design of specific primers for each patient specific target;

•  Sensitivity testing of all the primers/probe combinations; •  Sensitivity testing by modifying annealing temperature;

•  MRD detection experiment;

•  Parallel albumin analysis on each sample;

•  Final data calculation (normalization).

Page 14: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

It strongly depends on the therapeutic time point assessed:

•  Early time points •  the applicability of MRD could be higher as much as earlier is

the prognostic time point.

•  Late time points •  the persistence of residual blasts beyond 4 to 6 months or the

re-emergence of residual disease, even at the level of 1x10-4, predicts clinical relapse. However, the clinical usefulness of late MRD determination is limited.

Clinical impact of MRD

Page 15: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

I-BFM-SG ALL-MRD-Study: Update Outcome by MRD detection levels at w5 (tp 1) and w12 (tp 2)

MRD at tp. 1+2 neg.: 0.98, SE=.02 (N= 55, 1 event) MRD pos but < 10-3 at tp. 2: 0.76, SE=.06 (N= 55, 14 events) MRD at tp. 1+2 >=10-3: 0.16, SE=.08 (N= 19, 16 events)

years

p: 1-2: .0003; 1-3: .0001; 2-3: .0001 mrd

_upd

2.ka

m 0

2JA

N03

P

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

0 1 2 3 4 5 6 7 8 9 10 11

Basis for risk stratification in trial ALL-BFM 2000

Low risk group

Intermediate risk group

High risk group

Page 16: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

0

M

10 12

II

MR - 1

MR - 2

R2

H R 1'

H R 2'

H R 3'

III

BM sampling

12Gy*

* presymptomatic cranial irradiation (18[24] Gy for CNS pos. pts only) # selected indications for allo-BMT (in all strata of HR) ° SR: 2 molecular marker with a sensitivity of =<10-4 available (obligatory)

MRD Timepoints

1 2 (3) (4) (5)

II R1

SR°: •  no HR criteria •  MRD neg. at tps. 1+2

HR: MRD level at tp. 2 >=10-3 HR:

PRED-PR t(9;22) t(4;11) NR d33

20

12 Gy* only T-ALL

SR - 2

SR - 1

BFM

B M T#

III 12 Gy* only T-ALL

30/7/2000

22

1b

MR: •  no HR criteria •  no SR-criteria

III III III

III

II

29 26

II 18Gy*

12Gy*

II AIEOP

IA-D+

IA-P+

IB R

1a

G-CSF

104 W. 52 + IA-D: Protocol I, Phase A with DEXA IA-P: Protocol I, Phase A with PRED

10 weeks interim maintenance with 6-MP / MTX

H R 1'

H R 2'

H R 3'

R3

HR - 1

HR - 2

H R 1'

H R 2'

H R 3'

6-MP/MTX 4 Wks.

6-MP/MTX 4 Wks.

MRD as surrogate marker for risk-based

patient stratification

AIEOP-BFM ALL 2000 protocol

Page 17: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

MR: n = 1495

n=1495

MRD-MR n = 1708 (51%)

HR: n = 270

n=270

MRD-HR n = 270 (8%)

MRD classification feasible n = 3265 (77%)

Final risk group assignment in AIEOP-BFM ALL 2000 with and without MRD results (n=4239)

MRD classification not feasible n = 974 (23%)

SR: n = 1241

n=1241

MRD-SR n = 1287 (40%)

n=213 n=46

n = 424

n = 843 n = 131

n = 2338 n = 660 Final clinical risk groups (all eligible pts = 4239)

29% 55% 16%

Page 18: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

AIEOP-BFM ALL 2000 protocol: Outcome results

311 deaths 89.4%(0.7)5 yrs Prob.

SURVIVAL524 events 79.4%(1.1)

5 yrs Prob.

EFS

AIEOP-BFM 2000

4239 patients

CORS/Hannover - Apr 2006

Prob

abili

ty

0.0

0.2

0.4

0.6

0.8

1.0

YEARS FROM DIAGNOSIS0 1 2 3 4 5

1241N. pts

50N. events

91.4%(1.5)5 yrs EFS

SR 20002338

N. pts

281

N. events

78.8%(1.6)

5 yrs EFS

MR 2000660

N. pts

193

N. events

59.5%(3.2)

5 yrs EFS

HR 2000

AIEOP-BFM 2000by final risk

4239 patients

CORS/Hannover - Apr 2006

EFS

0.0

0.2

0.4

0.6

0.8

1.0

YEARS FROM DIAGNOSIS0 1 2 3 4 5

n=29%

55%

16%

by Final Risk n=4239

All BCP and T-ALL n=4239

1290N. pts

52N. events

91.5%(1.5)5 yrs EFS

SR1705

N. pts

200

N. events

75.7%(2.3)

5 yrs EFS

MR270

N. pts

114

N. events

36.8%(6.6)

5 yrs EFS

HR

AIEOP-BFM 2000by MRD

3265 patients

CORS/Hannover - Apr 2006

EFS

0.0

0.2

0.4

0.6

0.8

1.0

YEARS FROM DIAGNOSIS0 1 2 3 4 5

n=40%

51%

8%

by MRD n=3265

Page 19: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Definition of risk groups in ALL-BFM 95: SR: PRED-GR; WBC <20,000, and age 2-5y MR: PRED-GR; WBC >= 20,000, or age <1y, or >= 6y HR: PRED-PR, or induction failure, or Ph+ ALL

2552 15% 53% 32% All

215 (100%) 61% 29% 9% HR

1306 (100%) 16% 55% 29% MR

1031 (100%) 5% 55% 40% SR MRD risk criteria

ALL 2000

All HR MR SR

ALL-BFM 95 risk criteria

MRD risk groups of ALL-AIEOP BFM 2000 in comparison to risk groups according to ALL-BFM 95 criteria

(eligible patients classifiable by MRD)

Page 20: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Relapses in BCP-ALL by MRD risk groups AIEOP-BFM ALL 2000

1348 61 6.0%(0.8) 7.2%(1.2)1647 266 21.0%(1.2) 22.3%(1.4)189 60 34.9%(3.8) 38.5%(5.0)

SRIRHR

N.pts N. rel. 5-yrs CI 7-yrs CI

p-value<0.001

Cum

. Inc

iden

ce

0.0

0.2

0.4

0.6

0.8

1.0

Years from diagnosis0 1 2 3 4 5 6 7

Conter V et al Blood 2010; 115: 3206

Page 21: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Relapses in T-ALL by MRD risk groups AIEOP-BFM ALL 2000

75 5 7.6%(3.3)292 51 17.6%(2.2)97 36 37.7%(5.0)

SRIRHR

N.pts N. rel. 7-yrs CI

p-value: overall<0.001; SR vs MR=0.02; MR vs HR<0.001

Cum

. Inc

iden

ce

0.0

0.2

0.4

0.6

0.8

1.0

Years from diagnosis0 1 2 3 4 5 6 7

Schrappe et al. Blood 2011; 118: 2077

Page 22: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

401N. pts

13N. events

93.5%(1.9)5 yrs EFS

SR264

N. pts

27

N. events

67.5%(8.2)

5 yrs EFS

MR8

N. pts

3

N. events

58.3%(18.6)

5 yrs EFS

HR

AIEOP-BFM 2000TEL/AML pos - by MRD

673 patients

CORS/Hannover - Apr 2006

EFS

0.0

0.2

0.4

0.6

0.8

1.0

YEARS FROM DIAGNOSIS0 1 2 3 4 5

MRD-SR 1.0, SE=.00 (N= 6, no event)MRD-MR .50, SE=.15 (N=16, 6 events)MRD-HR .23, SE=.12 (N=18, 11 events)

years

Log-Rank p = .016

dsm

c040

5.ta

b 18

MA

Y05

P

0.00.10.20.30.40.50.60.70.80.91.0

0 1 2 3 4

Pts enrolledSep/Jul 00–Oct 04(Status April 05)

AIEOP + ALL-BFM 2000, EFS MRD Risk Groups, BCR/ABL pos

MRD results in genetically defined subgroups

BCR/ABL pos BCP-ALL (Pre-TKI)

t(12;21) n=673 pts

Page 23: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Summary of MRD results in childhood ALL

•  The long term EFS results of the retrospective MRD study confirmed the prognostic value of MRD monitoring at two early time points.

•  The cooperative AIEOP-BFM ALL2000 protocol was the first large multicentric trial using early MRD monitoring as a major prognostic factor for risk stratification in childhood ALL.

–  feasibility of early MRD monitoring in a large proportion of patients (~80%)

–  MRD confirmed its high prognostic value in all the biological subgroups of patients.

–  Definition of a large SR group with excellent outcome

Page 24: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

•  MRD-SR MRD negative at TP 1 and TP 2 with at least one, preferably more than one PCR-MRD marker with a sensitivity of at least 10-4

•  MRD-MR MRD positive at TP 1 and/or TP 2 and MRD at TP 2 <10-3 with at least one PCR-MRD marker

‚Slow early responders‘ (SER) MRD >10-3 at TP 1 and still positive at TP 2 by PCR-MRD

•  MRD-HR PCR-MRD >10-3 at TP 2 FCM-MRD >10% at d15 Hypodiploidy <44

•  PCR-MRD not stratified : FCM-MRD at d15: <0,1% SR

>0,1% and <10% MR

AIEOP-BFM ALL 2009: new MRD Risk Criteria

MRD stratification PCR : 94.0% FCM : 5.6% Overall: 99.6%

Page 25: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

N=1290, 52 events

AIEOP-BFM ALL2000 Outcome by number of markers

Pts enrolled Sep/Jul 00–Sept 05 (Status April 06)

years

P

0.0 0.1

0.2 0.3

0.4 0.5 0.6 0.7

0.8 0.9 1.0

0 1 2 3 4 5 6

.91, SE=.01

MRD-SR 2000 (at least 2 sensitive markers,

TP1 + TP2 negative)

.96, SE=.01

years

P

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

0 1 2 3 4 5 6

N=300, 11 events

MRD-MR 2000 (only 1 sensitive marker,

TP1 + TP2 negative)

Page 26: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Outcome of Childhood ALL by Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

Basso G. JCO 2009

Page 27: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

TP1 LOW+, TP2 NEG 0.83, SE=0.03 (N=305, 38 events) TP1 LOW+, TP2 POS 0.79, SE=0.05 (N= 97, 16 events) TP1 HIGH+, TP2 NEG 0.73, SE=0.05 (N=106, 28 events) TP1 HIGH+, TP2 POS 0.40, SE=0.07 (N= 89, 40 events)

years

Log-Rank p = <.0001

aieo

p_bf

m.ta

b 30

APR

09

P

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

0 1 2 3 4 5 6 7 8

AIEOP + ALL-BFM 2000 EFS (6 years) BCP-ALL, non-HR

Patient enrollment AIEOP: 09/00 – 07/06 BFM: 07/00 – 06/06 (Status June 08)

SER, slow early responers

Page 28: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

DI >1.6 .86, SE=.05 (N=59, 8 events) DI >1.16-<1.6 .87, SE=.01 (N=769, 99 events) DI >.81 -<1.16 .77, SE=.01 (N=3405, 680 events) DI <.81 .49, SE=.10 (N=24, 12 events)

ALL-BFM 90-2000 Age > 1 year EFS (5 years) DNA index

years

ehes

t090

5.ta

b 09

NO

V05

P

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

DNA Index<0.8 or < 44 chromosomes

DNA Index ≥1.16 or >50 chromosomes

Page 29: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

IB   M  IAD  

HR  

T/non-­‐HR  

pB#/non-­‐HR   M  

II  

IB  

AIEOP-BFM ALL 2009 pCRT  12  Gy  if  age  >  2  yrs*  /  in  selected  subgroups  no  CRT  +  6x    IT  MTX  

IA’  

IA  

IA  

R1  

Immunology  unknown  or  pB-­‐ALL  +  TEL/AML1  neg  +  FCM-­‐MRD  d15  >0.1%  

TEL/AML1  pos  and/or  FCM-­‐MRD  d15  <0.1%  

Prot.  IA  with  2  DNR  doses  (day  8  and  15)  

Prot.  IA  with  4  DNR  doses  (day  8,  15,  22  and  29)  

#  or  immunophenotype  unknown  *  in  paSents  with  CNS  disease  (CNS  3)  tCRT  with  12  Gy/18  Gy  (dose  age-­‐adapted))  

MR    II  

II  R2  

II  SR    

PEG-­‐L-­‐ASP  2500  IU/m2  every  2  weeks,  over  20  weeks  in  total  

PEG-­‐L-­‐ASP  4  x  2500  IU/m2  over  4  weeks  

IB+  

IB  

IA  

53   104  w  12  1   22   31   43  20  10  

IACPM  

RHR  

T-­‐ALL  

pB-­‐ALL#  

HR  1‘  

HR  2‘  

HR  3‘   III   III   III  

pCRT  12  Gy  if  age  >  2  yrs*  /  in  selected  subgroups  no  CRT  +  6x    IT  MTX  

„NRd33  only“  FCM  d15  >10%  

„MRD-­‐MR  SER“  „MRD-­‐HR  only“  

SCT  

DNX-­‐FLA  +  SCT  

IA’  IA  

Page 30: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

European Study Group on MRD detection in ALL (ex ‘ESG-MRD-ALL’; 57 laboratories in 23 countries)

− Standardization − Guidelines − Quality Control Rounds − Education − Developments

Page 31: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

EuroClonality NGS consortium

A. Langerak / J. van Dongen (Rdam)

P. Groenen (Nijmegen)

M. Brüggemann / C. Pott (Kiel)

M. Hummel (Berlin)

M. Catherwood (Belfast)

F. Davi (Paris)

E. Macintyre (Paris)

R. Garcia Sanz (Salamanca)

K. Stamatopoulos (Thessaloniki)

N. Darzentas (Brno)

G. Cazzaniga (Monza) J.Hancock (Bristol) J.Trka (Prague) M.Ladetto (Turin)

M. Lefranc / V. Giudicelli (Montpellier) Coordination : A.W. Langerak

Page 32: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

3. RQ-PCR design and sensitivity testing

4. MRD analysis of follow-up samples

2. MRD PCR target identification

1. DNA preparation

a. PCR-heteroduplex analysis

b. Sequencing of clonal rearrangements

c. Sequence interpretation

d. Selection of MRD-PCR targets

a. BM sampling at diagnosis (≥ 5ml)

b. MNC-density gradient separation (1x107 cells)

c. Genomic DNA extraction (≥ 10µg)

a. Design of allele-specific oligonucleotide primers

b. RQ-PCR analysis of dilution series of diagnostic sample

c. RQ-PCR data interpretation

a. RQ-PCR analysis of follow-up samples (control gene)

b. RQ-PCR analysis of follow-up samples (Ig/TCR targets)

c. RQ-PCR data interpretation

d. Calculation of MRD level

( 2-3 days )

( 1-2 weeks )

( 1-2 weeks )

( 1-2 weeks )

3. RQ-PCR design and sensitivity testing

4. MRD analysis of follow-up samples

2. MRD PCR target identification

1. DNA preparation

a. PCR-heteroduplex analysis

b. Sequencing of clonal rearrangements

c. Sequence interpretation

d. Selection of MRD-PCR targets

a. BM sampling at diagnosis (≥ 5ml)

b. MNC-density gradient separation (1x107 cells)

c. Genomic DNA extraction (≥ 10µg)

a. Design of allele-specific oligonucleotide primers

b. RQ-PCR analysis of dilution series of diagnostic sample

c. RQ-PCR data interpretation

a. RQ-PCR analysis of follow-up samples (control gene)

b. RQ-PCR analysis of follow-up samples (Ig/TCR targets)

c. RQ-PCR data interpretation

d. Calculation of MRD level

( 2-3 days )

( 1-2 weeks )

( 1-2 weeks )

( 1-2 weeks )

Flow diagram of RQ-PCR MRD diagnostics :

IG/TR sequencing

Bioinformatic analysis (data interpretation and

calculation of MRD levels)

Page 33: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Adult- ALL , Raff et al., Blood 2007

Early detection of relapse

17/28

5/77

13/15

Page 34: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Pediatric- ALL , Paganin et al., JCO 2014

Early detection of relapse

Page 35: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Major points still to be addressed: •  treatment context;

•  prospective validation;

• multivariate analysis.

How to integrate new novel genetic markers with MRD-defined subgroups?

Gene Expression Profiling SNParrays (copy number analysis)

Next Generation Sequencing

Page 36: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Novel genomic alterations with prognostic or therapeutic relevance

Gene/Subgroup Alteration Frequency Function Prognostic or therapeutic relevance

PAX5 Focal deletions, translocations, sequence mutations 30% of BCP-ALL Transcription factor required for B-

lymphoid development not related to outcome

IKZF1 Focal deletions or sequence mutations

15% of pediatric BCP-ALL cases Transcription factor required for

lymphoid development poor outcome 70-80% BCR-ABL1 ALL 35% of high-risk BCR-

ABL1negative ALL

JAK1/2

Pseudokinase and kinase domain mutations 20%-35% Down syndrome ALL

Constitutive JAK-STAT activation May be responsive to JAK inhibitors

10% high-riskBCR-ABL1negative ALL

CRLF2 IGH@-CRLF2 or P2RY8-CRLF2, resulting in overexpression

5%-15% pediatric and adult BCP-ALL, Associated with mutant JAK in up

to 50% of cases poor outcome >50% Down syndrome-ALL,

15% pediatric high-risk ALL Associated with IKZF1 alteration and JAK mutations

IL7RA Small ins/del and sequence mutations

10% pediatric T-ALL; <1% in BCP-ALL

Constitutive activation of the IL7 receptor; associated to CRLF2 rearrangements in BCP-ALL.

prognosis not known; may be responsive to JAK/STAT

inhibitors

SH2B3 Deletion and sequence mutations very rare in BCP-ALL, associated to BCR-ABL1-like

negative regulator of JAK2 signaling

May be responsive to JAK inhibitors

CREBBP Focal deletion and sequence mutations

20% of relapsed BCP-ALL; commonly acquired at relapse

Mutations result in impaired histone acetylation and

transcriptional regulation

Associated with glucocorticoid resistance

TP53 Deletions and sequence mutations

3% of BCP-ALL, commonly acquired at relapse

Loss of function or dominant negative poor outcome

BCR-ABL1-like GEP/CNA similar to BCR-ABL1 10% of BCP-ALL Activating cytokine receptor and kinase signaling

May be responsive to TKI or to JAK inhibitors

ETP T-ALL/myeloid immature immunophenotype 6-12% of T-ALL stem cell disease May be responsive to high-dose

cytarabine or epigenetic therapy

Adapted from ref.1. BCP-ALL= B-cell precursor Acute Lymphoblastic Leukemia, GEP=Gene Expression Profile; CNA=Copy Number Abnormalities; TKI=Tyrosine Kinase Inhibitor.

Page 37: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Mullighan C, Nature 2008;453:110

Mullighan C, N Engl J Med 2009;360:470

Impact of Ikaros deletions in childhood ALL

Validation Cohort, BCP, Ph- ALL (N=237) Validation Cohort, BCP ALL (N=258) Original Cohort (N=221)

Page 38: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Impact of Ikaros deletions in childhood ALL

DCOG protocol. Waanders E, Leukemia 2011;25:254

MRD / IKZF1 based stratification in non-HR

MRD-IR by IKZF1 status

MRD-LR/IR and IKZF1 wt

MRD-LR/IR and IKZF1 del

IKZF1 wt

IKZF1 mut

Page 39: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

DCOG-ALL-11 treatment protocol

M IA,IB IV MP/MTX

M MP/MTX+Dex/VCR

M HR1 MP/MTX

SR

MR

HR II

SCT

Risk group stratification: - MRD - prednisone response - CR day 33 - t(4;11)

IA,IB

IA,IB

HR2 HR3 HR1 HR2 HR3

Down/TELAML1: no anthr

IKZFdel: anthracycl

Other: anthracycl

MP/MTX+Dex/VCR

MP/MTX+Dex/VCR MP/MTX

Courtesy of Rob Pieters, DCOG

Treatment adapted on genomic lesions

Page 40: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Palmi C, Haematologica 2013;98:1226

overall

Intermediate Risk

Impact of Ikaros deletions in childhood ALL

n % n %SR 109 30,6% 8 2,2%IR 222 62,4% 42 11,8%HR 25 7,0% 4 1,1%

No YesIKZF1 deletionsFinal

stratification

Relapses in IKZF1 deleted: 0/8 SR vs 10/42 IR (23.8%) and 3/4 HR

Page 41: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

EFS and CIR by CRLF2 expression in BCP-ALL Intermediate risk patients

P=0.04 P<0.0001

P=0.24(solo rel) P=0.03(solo rel)

214N. pts

39N. rel.

17.6%(2.6)5 yrs Cum. Incidence

NEG15

N. pts

9

N. rel.

61.1%(12.9)

5 yrs Cum. Incidence

POS

pB AIEOP 2000Intermediate Risk - by CRLF2 deletion

229 patients

CORS - Nov 2010

Cum

. Incid

ence

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

YEARS FROM DIAGNOSIS0 1 2 3 4 5

10N. pts

1N. events

90%(9.5)5 yrs EFS

NEG10

N. pts

6

N. events

37.5%(16.1)

5 yrs EFS

POS

pB AIEOP 2000CRLF2>=20 - by CRLF2 deletion

20 patients

CORS - Nov 2010

EFS

0.0

0.2

0.4

0.6

0.8

1.0

YEARS FROM DIAGNOSIS0 1 2 3 4 5

Page 42: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

A new genomic subgroup : ‘Ph-like ALL’

Page 43: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Prognostic impact of Ph-like ALL

Mullighan C et al 2009; Loh M et al Blood 2013;121: 485-488

Den Boer ML et al 2009;

DFS

EFS

Cazzaniga G, ASH 2013 n. 353, Monday 9, 11:30 AM

p-value<0.001

1.0

0.8

0.6

0.4

0.2

0.0

EFS

0 1 2 3 4 5

BCP-ALL Total

Ph-like clustering

Case No. 235 11 (4.7%)

Age (mean) 5.7 10.3

WBC count 35,389 157,506

4-year EFS 83.20% 66.70%

Kiyokawa N, ASH 2013 n. 352, Monday 9, 11:15 AM

Page 44: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Kinase alterations in US Ph-like (detectable by multiplex RT-PCR)

Adapted from Mullighan, ASH 2013

Gene Drug n° of partners n° of cases partner genes

ABL1 Dasatinib 6 13 ETV6, NUP214, RCSD1, ZMIZ1, RANBP2, SNX2

ABL2 Dasatinib 3 7 RCSD1, ZC3HAV1, PAG1

CSF1R Dasatinib 1 4 SSBP2

PDGFRB Dasatinib 3 8 EBF1, ZEB2, TNIPI

CRLF2 JAK2 inhibitor 2 IGH, P2RY8

JAK2 JAK2 inhibitor 10 19 BCR, ETV6, PAX5, SSBP2, EBF1, others

EPOR JAK2 inhibitor 2 9 IGH, IGK

Page 45: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

EBF1-PDGFRB (Ph-like) responds to TKI

Weston BW et al, J Clin Oncol. 2013;31:e413-6

Lengline E et al, Haematologica. 2013;98:e146-8

days

Page 46: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Conclusions

•  Childhood ALL has become a paradigm of success in modern oncology. Still treatment failure rate is 15-20%.

•  Response (MRD) oriented risk stratification cannot yet be fully replaced by genetic markers at time of diagnosis.

•  New risk groups are being defined but their characterization is still not standardized.

•  Need to minimize long-term health complications in the large population of leukemia survivors.

•  Need for new drugs, new statistical methods, and transnational collaborations across large and well-characterized patient populations.

Page 47: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Acknowledgments Lilia Corral Simona Songia Tiziana Villa Eugenia Mella Valentina Carrino Giuseppe Gaipa Oscar Maglia Simona Sala Laura Levati Vincenzo Rossi Andrea Biondi Valentino Conter Giuseppe Masera Daniela Silvestri Maria Grazia Valsecchi Fondazione Tettamanti

Emanuela Giarin

Maddalena Paganin Katia Polato

Barbara Buldini

Barbara Michelotto

Giuseppe Basso

Clinica Ped. Univ. Padova

Grants by Fondazione Cariplo, AIRC and Comitato M.L.Verga

BFM Germany BFM Austria BFM Suisse

Page 48: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni
Page 49: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

AIEOP Center

•  Immunophenotyping •  Cytomorphology (diagnosis) •  Evaluation of response (d8) •  Preparation of DNA (d0, d33, w12) •  Banking of Cells and DNA •  MRD of local patients

Padova (centralized)

If material is insufficient: phone call for repuncture

Molecular genetics: •  Translocations (RNA) •  MRD:

•  Identification of MRD targets •  Testing of specifity and sensitivity

•  MRD quantification of follow up time points

•  Interpretation of results

•  DNA of diagnosis •  DNA of follow up time points

Genetics and MRD result for final risk group assignment

Flow diagram of diagnostic management

Monza

Page 50: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Definition of MRD in AIEOP-BFM ALL 2000

•  SR: MRD negative on day 33 (post-induction,TP1), and at day 78 (before "Prot. M" = TP2), if measured with at least 2 markers with a sensitivity of at least 10-4.

•  MR: no "SR-MRD" or "HR-MRD" criteria are met.

•  HR: MRD at time point 2 (d 78) is positive at ≥10-3.

Page 51: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

How to integrate MRD in the design of the new childhood ALL

treatment protocol ?

Page 52: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

1) FCM-MRD @d15 >10% ! HR 2) Stratification of patients who are not stratifiable by

PCR-MRD (and without classical HR criteria):

FCM-MRD @d15 <0,1% ! SR >0,1% and <10% ! MR

-> Stratification in >95% of patients

Role of FCM-MRD d15 for the stratification in AIEOP-BFM 2009

Page 53: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

How to integrate MRD in the design of the new ALL treatment protocol ?

•  MRD detection, currently the best available individual

risk assessment method, was available for stratification in almost all patients (combined use of PCR and FCM)

•  R1: Treatment reduction for low-risk pts but controlled by MRD

•  R2: Targeted and monitored intensification for all pts with intermediate relapse risk

•  R3: Early targeted and monitored intensification in high risk pts

Page 54: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Perspectives

•  MRD is generally used in ALL to guide post induction or post consolidation therapy.

•  Whilst it is unlikely that MRD studies could be completely replaced by novel risk factors, the combined use of MRD evaluation and the newly available genomic information on leukaemia presenting features, like Ikaros or CRLF2 gene deletions will further improve risk assignment of ALL patients.

•  However, clinically relevant improvements in ALL treatment can only result if MRD-based stratification is paralleled by the finding of the appropriate therapeutic strategy.

Page 55: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Monitoraggio molecolare della malattia minima residua nelle leucemie acute pediatriche:

standards o ricerca ?

Page 56: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Prerequisites of a reliable technique to detect MRD

a. Sensitivity of at least 10-4, although it depends on the clinical question;

b. Specificity, to prevent false-positive results c. being quantifiable within a large dynamic range; d. stability over-time of leukaemia-specific markers, to prevent false-

negative results, particularly in long-term studies; e. reproducibility between laboratories (essential for multicenter

trials); f. careful standardization and quality control checks; g. rapid availability of results (in time for clinical usefulness)

Page 57: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Problems and pitfalls of MRD-PCR detection via Ig/TCR genes

1.  Time consuming, labor intensive and expensive •  Target identification, selection and testing: 3-4 weeks •  RQ-PCR analysis of follow-up samples:1-2 weeks

2. Extensive knowledge and experience needed: •  Structure of Ig/TCR genes and rearrangement processes •  Ig/TCR gene rearrangement patterns in ALL (precursor-B-

ALL ↔ T-ALL; children ↔ adults)

3. International comparability of MRD-PCR results •  Between MRD-PCR centers of same treatment protocol •  Between treatment protocols

→ Standardization, guidelines and quality control

Page 58: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

European Study Group on MRD detection in ALL (EuroMRD)

AIMS of ESG-MRD-ALL (initial focus on PCR analysis of Ig/TCR genes): 1. Quality Control Program: 2 times per year: - February / March

- August / September

2. Educational meetings, including evaluation of quality control rounds: 2 times per year: - April / May - October / November

3. Standardization of MRD techniques - standardization techniques within each treatment protocol - guidelines for interpretation of RQ-PCR results

4. Collaborative development and clinical evaluation of new MRD strategies and new MRD techniques

Basis for accreditation of laboratory diagnostics

Page 59: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni
Page 60: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

EuroMRD collaborative history

1993  

Start IG/TcR analysis in I-

BFM

Page 61: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Quality Control within the EuroMRD-ALL

Positive 1.00E-05 1.00E-04 1.00E-03 1.00E-02

Mea

n

QR: 5x10-4

RQ-PCR analysis of a follow-up sample using provided primers/probe set

→ MRD level differs less than 2-fold between various laboratories

MRD-PCR laboratories 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Page 62: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

QR 21 Task 1: QR, S, MRD1 and MRD2

0

10

20

30

40

50

60

70

80

90

100

case 1 case 2 case 3 case 4 case 5 case 6 case 7 case 8 case 9 case 10

Perc

ent o

f lab

s wi

th s

ame

resu

lt

QRSMRD 1MRD 2

Inter-laboratory concordance on QR, sensitivity, MRD1 and MRD2

Page 63: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Subclonal architecture in ALL

Linear

Moderate Complex

Anderson, Nature 2011 Notta, Nature 2011

Page 64: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Darwinian clonal evolution of a cancer

Evolutionary speciation, from Charles Darwin's

(1837) Greaves, M. Cancer stem cells: back to Darwin? Semin. Cancer Biol. 20, 65–70 (2010).

Page 65: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Changes in clonal architecture in ALL

Page 66: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Clonal relationship of diagnosis and relapse samples in ALL

Mullighan, C. G. et al. Science 322, 1377–1380 (2008).

Page 67: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Perspectives : Clinical use of MRD

1.  Identification of subgroup of patients with different kinetic of early tumor reduction

2.  Identification of patients with different outcome within genetically homogeneous subgroups

3.  Identification of impending relapse

4.  ‘Molecular relapse’ ?

Page 68: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Prospective MRD monitoring in chilhood ALL for molecular relapse detection ?

•  Systematic controls for MRD on all patients have relatively low chances (in children) to identify “MRD relapses”

•  MRD monitoring may be quite stressful (for patients/families and labs)

•  HR subgroups could be more suitable for a strategy of MRD monitoring

•  A second sample for confirmation of MRD positivity should be required

Page 69: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

MRD as surrogate marker for early assessment of novel therapies?

"  The pressure to accelerate approval of novel drugs or the attempt to shorten the time to trial results has generated a growing interest on the use of end-points on activity (response) as surrogate end-points for efficacy (survival or event free survival).

" However, deciding that efficacy of treatment can be assessed in terms of molecular response requires that MRD levels are properly validated as a surrogate end-point.

Page 70: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni
Page 71: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

An  end-­‐point  for  acSvity  is  not  necessarily  a  surrogate  for  efficacy  

AcSvity          or              Efficacy  

MRD  as  surrogate  end  point  

‘…  It  has  to  be  pointed  out  that  surrogate  markers  cannot  serve  as  final  proof  of  clinical  efficacy  or  long  term  benefit.  If  they  are  intended  to  be  the  basis  for  regulatory  review  and  approval  then,  unless  they    are  properly  validated,  there  should  be  a  predetermined  plan  to  supplement  such  studies  with  further  evidence  to  support  clinical  benefit,  safety  and  risk/benefit  assessment.’  EmeaCHMP/EWP/83561/2005  

MRD                                                                                    EFS-­‐Survival  

early  response                          or                  clinical  outcome  

Page 72: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Conclusions ‘standards or research’?

"  ‘Standard’ •  Indepenent prognostic value at end-induction •  Standarized method •  Quality control rounds

"  ‘Research’ •  MRD depends on treatment and time points -> no clear value

outside clinical protocols •  Clonal background and evolution •  Combination of MRD and new genetic biomarkers •  Validation as a surrogate marker of efficacy •  Future use of next generation sequencing (development and

validation) •  Biology of different response (MRD) ?

Page 73: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Molecular MRD monitoring

in chilhood AML

Page 74: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

(…) AML is lagging behind acute lymphoblastic leukemia with respect to the implementation of MRD criteria for guidance during therapy. AML is particularly disadvantaged compared with ALL in that approximately half of AML patients lack a molecular target suitable for MRD monitoring.

Elisabeth Paietta. Minimal residual disease in acute myeloid leukemia: coming of age. ASH 2012 - Eucational

Page 75: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Molecular targets for MRD quantification in AML

#  Fusion transcripts - t(8;21)(q22;q22) / AML1-ETO - inv(16) or t(16;16)(p13q22) / CBFβ-MYH11 15% of cases RNA, non-linear correlation with cells Pre-leukemia/SC monitoring

#  Mutations (allele specific primers)

ex. NPM1, FLT3-ITD low mutation rate in chilren unstable targets

#  Overexpression

ex. WT1, EVI1, PRAME

Page 76: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

WT1 expression monitoring in chilhoo AML

•  Various methodologies to quantify WT1 expression •  Aim: To standardize WT1 mRNA quantitation the

European Study Group on WT1 Expression in Childhood AML was established including centers from Germany, Italy and Czech Republic

Page 77: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

WT1 Quality controls

Leukemia 2009, 23 (8), 1472-1479 - Standardization of WT1 mRNA quantitation

Page 78: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

WT1 expression in AML and healthy BM

2 log 20%

PB

Page 79: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Acknowledgments Lilia Corral Simona Songia Tiziana Villa Eugenia Mella Valentina Carrino Giuseppe Gaipa Oscar Maglia Simona Sala Laura Levati Vincenzo Rossi Andrea Biondi Valentino Conter Giuseppe Masera Daniela Silvestri Maria Grazia Valsecchi Fondazione Tettamanti

Emanuela Giarin

Maddalena Paganin Katia Polato

Barbara Buldini

Barbara Michelotto

Giuseppe Basso

Clinica Ped. Univ. Padova

Grants by Fondazione Cariplo, AIRC and Comitato M.L.Verga

BFM Germany BFM Austria BFM Suisse

Page 80: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni
Page 81: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Surrogacy requires that the effect of the intervention on the ‘candidate’surrogate predicts its effect on

true clinical outcome

Prentice’s definition

Treatment Surrogate Clinical

X

Surrogate endpoint needs to be validated It is treatment (class) specific

Page 82: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

“Surrogate  scenario”  

40%  10%  

4   24  

28  

40%  10%  

6   16  

22  

%  failures                      4  yrs  

n.  of  failed  

Same  rate  of  failures  in  responders/non  responders    

Modest  effect  on  clinical  outcome  

Standard  treatment  100  pts  

40   60  

YES   NO  

Experimental  treatment  100  pts  

60   40  

YES   NO  

High  ac`vity    

Response  

 

 

MG Valsecchi, CORS Monza

Page 83: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Main objective of the consortium is to develop, standardize, and validate IG / TR NGS tools for:

i.) clonality assessment; ii.) MRD analysis; iii.) repertoire analysis / somatic mutation analysis

Platform-independent assay design Scientifically independent group, no exclusive interactions with commercial partners in the field of NGS (whenever relevant and useful, collaboration will be initiated, for example for optimal dissemination of developed assays / tools)

EuroClonality-NGS consortium

Page 84: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

EuroClonality NGS consortium

A. Langerak / J. van Dongen (Rdam)

P. Groenen (Nijmegen)

M. Brüggemann / C. Pott (Kiel)

M. Hummel (Berlin)

M. Catherwood (Belfast)

F. Davi (Paris)

E. Macintyre (Paris)

R. Garcia Sanz (Salamanca)

K. Stamatopoulos (Thessaloniki)

N. Darzentas (Brno)

G. Cazzaniga (Monza)

M. Lefranc / V. Giudicelli (Montpellier) Coordination : A.W. Langerak

Page 85: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Phase 1 Technical WorkPackages

1 Development of IG-TR PCR-based NGS assays (all teams)

2 Bioinformatics pipeline (N. Darzentas)

3 Capture-based NGS strategies (D Gonzalez)

Phase 2 Application WorkPackages

4 NGS-based clonality assessment (P. Groenen / M. Hummel)

5 NGS-based MRD assessment (M. Brüggemann / C. Pott)

6 NGS-based Ig repertoire analysis (F. Davi / K. Stamatopoulos)

7 NGS-based TR repertoire analysis (A. Langerak / E. Macintyre)

EuroClonality-NGS consortium

Page 86: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Position IGH

V-J

IGH

D-J

IGK

V-J / V-Kde

IGL

V-J

TRB

V-J / D-J

TRG

V-J

TRD

V-J / D-D/J

“FR3”

(clonality,

MRD)

~200 bp

Kiel

Salam.

Paris-P

Thess

Nijmegen

Rotterdam

Belfast

NOT Berlin

Kiel

Monza

Paris-N

London

Paris-N Monza

London

“leader”

(repertoire) Paris-P n.a.

(phase 2?)

t.b.d.

(phase 2?)

t.b.d. NOT NOT NOT

EuroClonality-NGS – PCR-based assays

Page 87: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

454 GS Flex, Junior (Roche) HiSeq, MiSeq (Illumina)

Ion Torrent (Life)

Platform independence

Page 88: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

•   wet  lab  work  • 'raw'  data  from  the  NGS  machine  

• data  preparation,  including  error  correction  

• meta-­‐analysis,  e.g.  IMGT/HighV-­‐QUEST      Nikos  Darzentas  Vojta  Bystry  Jana  Silhava    Bioinformatics  Analysis  Team  -­‐  BAT  -­‐  bat.infspire.org    Central  European  Institute  of  Technology  -­‐  CEITEC  Masaryk  University  -­‐  MU  Brno,  Czech  Republic  

EuroClonality-NGS – Bioinformatic pipeline

Page 89: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

basic  major  steps    00.  everything  is  logged,  in  different  formats  01.  parameter  choice,  can  be  defaults,  can  be  organised  in  'scenarios'  02.  reading  files,  counting  sequences,  handling  data  03.  if  applicable:  joining  paired-­‐end  reads  04.  if  applicable:  across-­‐samples  comparison  and  info  gathering  05.  primer  /  adapter  cutting  06.  quality  trimming,  filtering,  masking  07.  FASTQ  to  FASTA  08.  dereplicating  09.  error  correction  10.  final  filtering  steps  11.  junction  analysis,  summaries,  matrices,  visualisations  12.  wrapping  up  -­‐  minilogging,  compressing/removing  files      

EuroClonality-NGS – Bioinformatic pipeline

Nikos Darzentas

Page 90: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

error  correction    error  corrections  are  attempted  through  a  module  that  can  be  repeated  as  many  times  as  requested  or  required    there  is  actually  an  'auto'  mode  that  goes  on  (within  limits)  until  it  reaches  a  plateau  of  small  number  of  corrections    error  correction  decisions  can  be  different,  for  many  reasons:  -­‐  for  different  sequence  regions,  e.g.  V,  junction,  J  etc.  -­‐  for  different  receptors,  i.e.  IG  and  TR  -­‐  for  different  samples,  runs,  machines,  protocols    critically,  we  can  learn  on-­‐the-­‐fly  from  a  sample  or  sequence  region  (e.g.  V  region  in  TR,  which  should  be  in  germline-­‐configuration)  to  apply  in  another  region  (e.g.  junction)  or  other  samples    there  can  also  be  multiple  individual  factors  affecting  the  decisions,  e.g.  strand  biases  

EuroClonality-NGS – Bioinformatic pipeline

Nikos Darzentas

Page 91: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

 cluster  19                    10                20                30                40                50                60                70                80                90                100              110              120          .        |        .        |        .        |        .        |        .        |        .        |        .        |        .        |        .        |        .        |        .        |        .        |        .  gagctctgtgaccgccgcggacacggctgtgtattacTGTTCGAGCAGCTTAGGTGTGGCAGTNGCTGGTACGGGTTCGGACTACTTTGAGCAATGGagccagggaaccngggtcaccgtctcctcag                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  g                                                                                                                t                                                                                                                                                g                                                                                        n                                                                                                                                                                        g                                                                                                                                                                      -­‐                                                                                                                                                                                                                                                                                                                                          t                  g                                                                                                    a                                                                                                                                                        n                                          |after  corrections                                                                                                                                -­‐                                                                                          g                                                                                                                                                                      -­‐                                                                                          g                                                                                                                t                                                    -­‐                                                                                          g                                                                                                                                                                      -­‐                                                                                          g                                                                                                                                                                      -­‐                                                                                          g                                                                                                                                                                      -­‐                                                                      t                  g                                                                                                    a                                                                -­‐                                                                                          g                                        

EuroClonality-NGS – Bioinformatic pipeline

Nikos Darzentas

Page 92: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

Exome Capture – TruSeq (Illumina) DNA $ Fragmentation ~200 bp $ Library Prep $ Hybridisation to biotin-DNA baits $ Streptavidin pull down $ Amplify/index $ Sequence

EuroClonality-NGS – Capture-based assays

Page 93: Nuovi markers bio-molecolari nelle Sindromi ... · Nuovi markers bio-molecolari nelle Sindromi Linfoproliferative La Leucemia Acuta Linfoblastica Genova, 11 Novembre 2014 Alterazioni

BCL2 IGH

FFPE

FF

EuroClonality-NGS – Capture-based analysis

David Gonzalez ! to be extended to V(D)J rearrangements (IG-TR)